Abstract:Introduction Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD), affects 30% globally, potentially leading to cirrhosis. Metabolic dysfunction-Associated Steatohepatitis (MASH) often involves platelets. Platelet roles in MASLD progression remain underexplored. Aim Our aim was to verify the possible platelet contributions to MASLD/MASH genesis and in MASLD-related cirrhosis, compared to healthy subjects, investigating the activation state of platelets in vitro and in vivo. Materials and Methods Patients with metabolic liver cirrhosis (Child-Pugh classes A/B), MASLD/MASH, and healthy volunteers without metabolic alterations were examined. Patients were diagnosed trough abdominal ultrasounds, TC, RM and liver biopsy, Fibroscan and other non-invasive test and scores were also used. Microfluidic analysis assessed platelet adhesion on collagen, indicating pre-activation states and in vitro activation levels. Urinary 11-dehydro-thromboxane-B2 (11-TXB2) measured in vivo thromboxane A2 synthesis, indirectly assessing platelet activation in vivo. Platelet interaction with coagulation factors, specifically Factor VIII (FVIII) and von Willebrand Factor (vWF) activity, was explored through cross-mixing experiments. Results Among 66 participants, platelet count was significantly lower in cirrhotic patients compared to controls (p<0.001). However, no differences were observed in platelet distribution width, mean platelet volume, or immature reticulate fraction among the three cohorts. In vitro adhesion on collagen was higher in MASLD/MASH and cirrhosis (p<0.01) compared to controls. 11-TXB2 levels were significantly elevated in cirrhotic patients compared to controls (p<0.001). Higher levels of FVIII and vWF were observed in the platelet-poor plasma (PPP) of cirrhotic patients. Cross-mixing experiments indicated that elevated FVIII and vWF levels in cirrhotic patients were associated with these factors in PPP rather than a direct contribution from washed platelets. Conclusions MASLD/MASH showed normal platelet counts, but increased adhesion, suggesting pro-inflammatory and pro-fibrotic roles. In contrast, cirrhotic patients displayed reduced platelet count, but increased adhesion function. They also exhibit significantly higher 11-TXB2 levels compared to controls, suggesting higher in-vivo platelet activation.

Role of Perturbated Hemostasis in MASLD and Its Correlation with Adipokines

Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments

Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and Challenges

Metabolic dysfunction-associated steatotic liver disease: A pathophysiology and clinical framework to face the present and the future

Updated mechanisms of MASLD pathogenesis

Innate Immunity and MASLD

Roles of immune dysregulation in MASLD

Role of MASLD in CVD: A review of emerging treatment options

Exploring the Role of Peroxisome Proliferator-Activated Receptors and Endothelial Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease

MASLD: a systemic metabolic disorder with cardiovascular and malignant complications

Role of pattern recognition receptors in the development of MASLD and potential therapeutic applications

The Proteomics of MASLD Progression: Insights From Functional Analysis to Drive the Development of New Therapeutic Solutions

Mechanism of Metabolic Dysfunction-associated Steatotic Liver Disease: Important role of lipid metabolism

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review

Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic

From Hypothalamic Obesity to Metabolic Dysfunction-Associated Steatotic Liver Disease: Physiology Meets the Clinics via Metabolomics

Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review

Therapeutic implications for sphingolipid metabolism in metabolic dysfunction-associated steatohepatitis

Tiny but powerful: platelets behaviour in metabolic dysfunction-associated steatotic liver disease and its evolution to liver cirrhosis

Targeting the Adipose Tissue–Liver–Gut Microbiota Crosstalk to Cure MASLD

Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease